8.2. Analysis.
Comparison 8 Non‐comparative studies: proportion of participants withdrawn from methylphenidate treatment due to non‐serious adverse events, Outcome 2 Proportion of participants withdrawn from methylphenidate for unknown reasons.
| Proportion of participants withdrawn from methylphenidate for unknown reasons | |
|---|---|
| Study | |
| Akhondzadeh 2003 | 4/14 |
| Akhondzadeh 2004 | 2/22 |
| Altin 2013 | 30/204 |
| Amiri 2008 | 3/30 |
| Ardic 2014 | 21/122 |
| Balázs 2011 | 3/37 |
| Barbaresi 2006 | 84/379 |
| Bereket 2005 | 58/72 |
| Chou 2012b | 34/296 |
| Dirksen 2002 | 13/310 |
| Dittmann 2014 | 52/247 |
| El‐Zein 2005 | 6/18 |
| Findling 2009 | 109/326 |
| Findling 2010 | 54/162 |
| Gadow 1995 | 7/34 |
| Galland 2010 | 2/30 |
| Gau 2008 | 13/137 |
| Germinario 2013 | 161/351 |
| Guerreiro 1996 | 2/24 |
| Haertling 2015 | 16/262 |
| Hammerness 2009 | 97/152 |
| Hong 2012 | 5/112 |
| Jensen 1999 (MTA) | 29/144 |
| Kim 2011 | 5/102 |
| Kim 2014b | 12/75 |
| Kim 2015a | 49/86 |
| Klein 2004 | 9/129 |
| Lee 2009 | 6/144 |
| Lee 2012 | 22/93 |
| Li 2011 | 2/36 |
| McCracken 2016 | 6/69 |
| Mohammadi 2004 | 5/16 |
| Mohammadi 2012a | 8/32 |
| Mohammadi 2012b | 3/23 |
| Peyre 2012a | 37/173 |
| Poulton 2003 | 6/19 |
| Remschmidt 2005 | 26/89 |
| Shang 2015 | 11/80 |
| Sobanski 2013 | 29/381 |
| Steele 2006 | 4/73 |
| Tasdelen 2015 | 2/22 |
| Walitza 2009 | 15/26 |
| Wang 2007 | 7/166 |
| Wang 2011 | 17/50 |
| Warshaw 2010 | 28/305 |
| Weber 2003 | 8/57 |
| Weiss 2007 | 3/90 |
| Wigal 2013 | 3/45 |
| Wilens 2005 | 140/407 |
| Wilens 2006 | 36/171 |
| Witt 2008 | 9/34 |
| Yalcin 2014 | 2/40 |
| Yang 2012 | 12/130 |
| Zarinara 2010 | 1/19 |
| Zheng 2011 | 202/1447 |
| Zheng 2015 | 25/153 |
| Çetin 2015 | 7/73 |